Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2009

BG Medicine, NHLBI, and Boston University Partner for Cardiovascular Biomarker Discovery

  • BG Medicine, the National Heart, Lung, and Blood Institute (NHLBI), and Boston University (BU) will jointly undertake biomarker discovery studies for heart disease and early detection of metabolic syndrome.

    Under this CRADA, BG Medicine's technology will be used to analyze biosamples obtained during years of collection by Framingham Heart Study researchers. The Framingham Heart Study is funded by NHLBI and conducted in collaboration with BU's School of Medicine and School of Public Health.

    Only information from participants who have consented to sharing their specimens and data with commercial researchers will be used, and all shared information will be de-identified to protect participants' privacy.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »